RE: Waken up guys13 Aug 2020 12:49
TF, thanks for your comments
Ray, thank you for contributing to the debate.
I know many have said that it is pointless having an argument around valuation. I agree, it is impossible to put a precise value at this early (after 10 years!) stage but I disagree it is "pointless". As a professional forecaster, you have to accept it impossible to get things spot on but that doesn't mean you give up getting as close as possible and resort to guessing.
If you feel otherwise, please move on........
The initial question regarding the "extra" £3.2 billion on the perceived value came about from Inan's "£8 still works for me" comment. He is quite entitled to his opinion (as I am mine) but I'm afraid £8 DOESN'T work for me. In the formula:
Company_Value = Shares_In_Issue x SP
Or
SP = Company_Value / Shares_In_Issue
for the SP to remain constant when the shares in issue changes, then the other variable - Company Value) HAS to change. In this case from £1.8 Billion to £5.0 Billion (over a four year period).
Ray, I accept your point about the enhanced value of Immunobody over the past four years - but, was that already factored in to the £1.8 Billion valuation?
Personally, I'm a little uneasy that 64% of the value of Scancell has been produced in the past four years. Isn't that grossly devaluing the contribution of Immunobody and Moditope? I'd go the other way round and say that 66% of the value was already there 4 years ago. So IF it was £8 per share 4 years ago, we are now looking at £4.29 per share (£3.80 fully diluted)
Please note, I am not endorsing the £8/share valuation of 4 years ago, simply stating that IF that WERE correct, then this is where we would be now taking into account dilution and additional IP value for Avidimab.
If you don't want to discuss values and you have read this far - it's your own fault :)